Clinicians’ Feedback on Patient/Carer Experience After Switching of Growth Hormone Treatment in Pediatric Patients During COVID-19 by Blair J, Warth K, Suvarna Y, Cappa M

Get full text

Naloxone inhibits exercise-induced release of PRL and GH in athletes. by Moretti, C, Fabbri, A, Gnessi, L, Cappa, M, Calzolari, A, Fraioli, F, Grossman, A, Besser, G

Deficiency of immunoregulatory indoleamine 2,3-dioxygenase 1in juvenile diabetes. by Orabona, C, Mondanelli, G, Pallotta, MT, Carvalho, A, Albini, E, Fallarino, F, Vacca, C, Volpi, C, Belladonna, ML, Berioli, MG, Ceccarini, G, Esposito, SM, Scattoni, R, Verrotti, A, Ferretti, A, De Giorgi, G, Toni, S, Cappa, M, Matteoli, MC, Bianchi, R, Matino, D, Iacono, A, Puccetti, M, Cunha, C, Bicciato, S, Antognelli, C, Talesa, VN, Chatenoud, L, Fuchs, D, Pilotte, L, Van den Eynde, B, Lemos, MC, Romani, L, Puccetti, P, Grohmann, U